Gene Therapy for Muscular Disorders

Copy of Comparability Banner (1)

With clinical holds lifting there has been more investment and clinical progress in the gene therapy for muscular disorders space than ever before, yet the consequences of toxicity are not a distant memory. Despite the successes, there are still withstanding challenges for gene therapy developers targeting the muscle when it comes to optimizing delivery and navigating toxicity to develop truly safe and transformative therapeutics for muscular disorders patients.

The first industry-dedicated Gene Therapy for Muscular Disorders Summit will focus on overcoming the translational and clinical challenges of developing genetic therapies targeting muscular disorders, including Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy (LGMD), Pompe Disease and X-Linked Myotubular Myopathy.

Join your fellow industry leaders from the likes of PTC Therapeutics, Solid Biosciences, Pfizer, AskBio Novartis at this digital event in March.

View the event guide here for the full meeting details!

Hanson Wade

Hanson Wade

21 January, 2021